NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the benefits of NGS in oncology.
- Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and others highlight! the importance of NGS in treatment planning.
Next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
Additional experts such as Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Roboz, MD, contribute to the discussion.
Author's summary: NGS enhances biomarker testing in solid tumors.
More News
- Battlefield 6’s New Free-To-Play Battle Royale Mode Launches Tomorrow
- SJHN Daily: Celebrini Named NHL First Star of the Week
- 400,000 Coloradans have cast votes so far
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Desperate need for water and food continues as Gaza families head north
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Sweden’s still ahead in the preparedness game — and now it means business
- Importing beef is not the solution | GABEL
- Anglicans need more than one boat - THE OTHER CHEEK